Mercy Investment Services at AbbVie, Amgen, Biogen, Eli Lilly, Pfizer

What happened

Result: Filed on 14 November 2019 for the 2020 proxy season at AbbVie, Amgen, Biogen, Eli Lilly and Pfizer, with Mercy Investment Services lead filer at Amgen and Eli Lilly and United Church Funds leading the engagement with AbbVie. It reached a vote at two of the five. AbbVie, 8 May 2020: not approved, 249,382,082 for, 773,211,511 against, 19,752,693 abstaining and 251,100,201 broker non-votes, or 24.4 percent of the votes cast for and against. Eli Lilly, 4 May 2020: not approved, 184,652,906 for, 570,094,648 against, 27,534,077 abstaining and 83,997,305 broker non-votes, or 24.5 percent. No proposal on drug pricing and executive pay appears in the certified results of Amgen's meeting on 19 May 2020, Biogen's on 3 June 2020 or Pfizer's on 23 April 2020.

Neither vote came close to a majority, and we found no change to an executive compensation arrangement at any of the five companies documented in the pages we opened. Why the proposal did not reach a vote at Amgen, Biogen or Pfizer is unsettled: a withdrawal after agreement and an exclusion granted by the SEC staff would both look like this in the certified results, and we did not open the no-action correspondence that would tell them apart.

Shareholders renew their campaign to curb escalating drug prices at U.S. drug makers, Interfaith Center on Corporate Responsibility

What this campaign is about

• Right to an adequate standard of living, security in sickness and old age, and special care for motherhood and childhood Pivotal · Universal Declaration of Human Rights